drugset / Trial / NCT03193047

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

NCT03193047

Phase 2 Completed 59 enrolled Esperion Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.

Timeline

Start
2017-04-07
Primary completion
2018-01-29
Completion
2018-02-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 180 mg Oral
Background Evolocumab Monoclonal antibody 420 mg

Indications